CRISPR Therapeutics Hits Day Low of $50.66 Amid Price Pressure

CRISPR Therapeutics AG experienced significant volatility on March 10, 2026, with the stock hitting an intraday low of USD 50.66. The company, operating within the Pharmaceuticals & Biotechnology sector, saw its shares decline by 10.17% for the day, contrasting sharply with the S&P 500's modest drop of 0.21%. Over the past week, CRISPR Therapeutics has faced a 9.06% decrease, while its performance over the last month remains positive at 8.13%. However, the stock's longer-term trajectory reveals challenges, with a notable 57.47% decline over the past five years. Financial metrics indicate a low return on equity of 3.15%, reflecting limited profitability relative to shareholder funds. The company has reported negative results for four consecutive quarters, with net sales plummeting by 95.17% and operating cash flow at a low of USD -345.01 million. Additionally, the return on capital employed stands at -30.18%, highlighting ongoing financial difficulties. As a small-cap entity with a market capitalization of USD 5,141 million, CRISPR Therapeutics continues to navigate a challenging landscape marked by fluctuating performance indicators.